Related Experiment Video
Updated: Jul 21, 2025
Evaluation of Zebrafish Kidney Function Using a Fluorescent Clearance Assay
Published on: February 20, 2015
Efficacy and Safety of Burosumab in X-linked Hypophosphatemia
Sen Wang1, Xiaoqin Wang1, Miao He2
1Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Context:
Burosumab is approved for the treatment of X-linked hypophosphatemia (XLH).
Objective:
To assess the efficacy and safety of burosumab in XLH patients, we conducted a systematic review and meta-analysis.
Methods:
We searched PubMed, the Cochrane Library, Embase, ClinicalTrials.gov, and Web of Science for studies on the use of burosumab in patients with XLH. Meta-analysis of randomized controlled trials (RCTs) and single-arm trials (SATs) was done to explore burosumab treatment on the efficacy and safety of XLH.
Results:
Of the 8 eligible articles, 5 were from RCTs and 3 were from SATs. Compared with the control group in RCTs, serum phosphorus level was significantly increased in the burosumab group (0.52 mg/dL, 95% CI 0.24-0.80 mg/dL). A meta-analysis of the burosumab arms in all trials revealed significant increase in serum phosphorus levels (0.78 mg/dL, 95% CI 0.61-0.96 mg/dL), TmP/GFR (0.86 mg/dL, 95% CI 0.60-1.12 mg/dL), and 1,25-dihydroxyvitamin D level (13.23 pg/mL, 95% CI 4.82-21.64 pg/mL) as well. Changes in secondary events also validated the effects of burosumab treatment. Compared with the control group, in RCTs, the safety profile of burosumab is not much different from the control group. Data of the single-arm combined group demonstrated the incidence of any treatment emergency adverse event (TEAE) and the related TEAE rate were high, but the severity of most adverse events is mild to moderate, and the rate of serious TEAE is low.
Conclusion:
This study suggests that burosumab can be an option for patients with XLH and did not significantly increase the incidence of adverse events.
